Jazz Pharmaceuticals

120.80
-0.38 (-0.31%)
At close: Jan 21, 2025, 9:38 AM
undefined%
Bid 120.4
Market Cap 7.30B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) 7.06
PE Ratio (ttm) 17.11
Forward PE n/a
Analyst Buy
Ask 121.2
Volume 23,088
Avg. Volume (20D) 595,293
Open 121.47
Previous Close 121.18
Day's Range 120.34 - 121.52
52-Week Range 99.06 - 134.17
Beta undefined

About JAZZ

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include ...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 1, 2007
Employees 2,800
Stock Exchange NASDAQ
Ticker Symbol JAZZ

Analyst Forecast

According to 14 analyst ratings, the average rating for JAZZ stock is "Buy." The 12-month stock price forecast is $174, which is an increase of 44.04% from the latest price.

Buy 78.57%
Hold 21.43%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Jazz Pharmaceuticals is scheduled to release its earnings on Feb 26, 2025, during market hours.
Analysts project revenue of $1.06B, reflecting a 4.74% YoY growth and earnings per share of 5.79, making a 15.34% increase YoY.
2 months ago
+6.75%
Jazz Pharmaceuticals shares are trading higher aft... Unlock content with Pro Subscription